Melanoma Molecular Maps Projects

Padova

Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;


  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);


  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.


Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.



LATEST NEWS
The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.




REFERENCE(S):

"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma.
Inzelberg R, Samuels Y, Azizi E, Qutob N, Inzelberg L, Domany E, Schechtman E, Friedman E
Neurol Genet. 2016 Jun;2(3):e70.
PMID: 27123489 [PubMed]

Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors.
Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, Tanase C, Chitu V, Caruntu C, Ghita M, Popescu C, Boda D, Mastalier B, Maru N, Daha C, Andreescu B, Marinescu I, Rebosapca A, Staniceanu F, Negroiu G, Ion DA, Nikitovic D, Tzanakakis GN, Spandidos DA, Tsatsakis AM
Oncol Lett. 2016 May;11(5):3354-3360.
PMID: 27123116 [PubMed]

Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review.
Fierz FC, Meier F, Chaloupka K, Böni C
Klin Monbl Augenheilkd. 2016 Apr;233(4):540-544.
PMID: 27116532 [PubMed - as supplied by publisher]

Blue Nevus-Like Metastasis of a Cutaneous Melanoma Identified by Fluorescence In Situ Hybridization.
Campa M, Patel M, Aubert P, Hosler G, Witheiler D
Am J Dermatopathol. 2016 Apr 19;():.
PMID: 27097332 [PubMed - as supplied by publisher]

Spatial analysis of incidence of cutaneous melanoma in the Friuli Venezia Giulia region in the period 1995-2005.
Cecconi L, Busolin A, Barbone F, Serraino D, Chiarugi A, Biggeri A, Catelan D
Geospat Health. 2016 Apr 18;11(1):422.
PMID: 27087039 [PubMed - in process]


NCBI's Disclaimer and Copyright notice